INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nutex Health, Inc. - NUTX

Core Viewpoint - Pomerantz Law Firm is investigating claims on behalf of investors of Nutex Health, Inc. regarding potential securities fraud or unlawful business practices by the company and its officers/directors [1] Financial Performance - Nutex Health, Inc. reported a revenue decrease of $105.9 million to $151.7 million for Q4 and fiscal year 2025, attributed to a one-time $55.0 million cumulative true-up of 18,950 arbitration claims deemed ineligible under the IDR process [1] - Following the announcement of these financial results, Nutex's stock price fell by $15.06 per share, or 14.3%, closing at $90.28 per share on March 6, 2026 [1] Legal Investigation - The investigation by Pomerantz LLP focuses on whether Nutex and certain officers/directors engaged in securities fraud or other unlawful business practices [1] - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a history of recovering multimillion-dollar damages for victims of securities fraud and corporate misconduct [1]